- Hiring a single consultant will solve the problem
- Nothing more wrong than this! A single consultant will never be able to cover the multiple interfaces and requirements of successful local market access.
- Reimbursement prices are very low.
- Wrong again! It is true that fewer products are reimbursed, but the ones, which are paid for, are similarly priced as in Western EU countries. This underlines the importance of professional planning and preparation only possible with profound market access experience and local knowledge.
- Reimbursement granted will stay on forever
- And wrong again! In the CEE region reimbursement might need to be renegotiated on a yearly basis in well prepared discussion rounds with reimbursement authorities.
- Getting the EU launch sequence wrong!
- We provide you with crucial information about expected pricings and the resulting launch plan to prevent later disappointment and losses.
5 Surefire Ways To Achieve Long Lasting Orphan Drug Market Access and Sales Success in Eastern European EU Countries
- Get a local partner company with a strong track record!
- They should be able to cover the full spectrum of market access including marketing and sales.
- Don’t relay on extrapolations for treatable patients!
- Have a team getting out there doing the real field work.
- Keep prices up across the region!
- Europe is a fragmented place and authorities tend to watch each other and tend to communicate. A sound pricing strategy makes or brakes the project.
- Leverage the power and influence of patient organisations!
- A well-organized patient organization helps to advance reimbursement decisions in a big way. Talk to them, engage them and help them with useful information.
- Focus on patient finding activities!
- This is key to grow your business and only a partner with an excellent network to the physicians can succeed.
4 Most Compelling Reasons Why To Work with a Local Orphan Drug Market Access, Pricing and Sales Partner in Eastern Europe (CEE)
- Language still a significant barrier!
- Significant time can be lost and process lengthened due to miscommunication. Relevant parts of reimbursement process change often rapidly and are not translated immediately or at all.
- Long-term control of payment streams is key!
- A local partner makes sure that you receive payments in time.
- No upfront investment in infrastructure needed!
- For rare and especially ultra rare diseases it is often not economical to set up a full infrastructure. A local company has it all and on top of it an excellent living network to doctors, KOLs, patient organizations and authorities.
- Health Technology Assessment (HTA)
- Added clinical benefit evaluation (similar to Western EU countries)
- Budget impact analysis (can differ significantly)
- Cost-effectiveness analysis (can differ significantly)